



---

Winter 2002

## Cell Transfer Restores Sperm Production in Infertile Mice

Stephen Bradt  
*University of Pennsylvania*

Follow this and additional works at: <https://repository.upenn.edu/bellwether>

---

### Recommended Citation

Bradt, Stephen (2002) "Cell Transfer Restores Sperm Production in Infertile Mice," *Bellwether Magazine*:  
Vol. 1 : No. 55 , Article 7.  
Available at: <https://repository.upenn.edu/bellwether/vol1/iss55/7>

This paper is posted at ScholarlyCommons. <https://repository.upenn.edu/bellwether/vol1/iss55/7>  
For more information, please contact [repository@pobox.upenn.edu](mailto:repository@pobox.upenn.edu).

# Cell transfer restores sperm production in infertile mice

By Stephen Bradt

Scientists at the School have successfully transplanted specialized cells that are critical to sperm development in mice, restoring sperm production in once-infertile animals.

The research may give scientists a better understanding of how Sertoli cells—which surround spermatogenic stem cells—nourish sperm production and the survival of stem cells.

“Spermatogenesis is a highly organized process, requiring just the right environment, or ‘niche,’ around the germ line stem cells,” said **Ralph L. Brinster, V’60**, professor of reproductive physiology at the School. “The Sertoli cells are essential to this environment, and it appears that by replacing them, we can essentially reconstruct the niche in which sperm development takes place.”

Much of the volume of a mammalian testis consists of tightly coiled seminiferous tubules that hold mature sperm. Sperm development also occurs within these tubules, which are home to spermatogenic stem cells, the seeds from which spermatogenesis arises. Seminiferous tubules are lined with Sertoli cells, which are thought to nurture sperm cells as they develop and facilitate their eventual passage out of the testis.

Brinster and colleagues worked with Steel mutant mice, which are congenitally infertile due to a Sertoli cell defect. Before inserting healthy Sertoli cells, the researchers treated the mice's testes with busulfan and cadmium to remove any defective germ cells and Sertoli cells. The seminiferous tubules remained, likely providing the structural support needed to completely reconstitute spermatogenesis from donor cells.

The Brinster group's technique for transplanting Sertoli cells will likely allow scientists to study stem cells' specialized environment in a way that has not been possible before. Currently, the best-studied stem cells are those that generate blood cells, even though these cells, which reside in bone marrow, are relatively inaccessible to researchers.

“I believe Dr. Brinster's new results have catapulted the spermatogenic stem cell system into a position of maximum experimental flexibility among all other stem cell systems in the body,” said John R. McCarrey, professor of cell and molecular biology at the University of Texas at San Antonio, who was not involved in

this work. “This may lead to significant new insight into the manner in which the spermatogenic stem cell works in particular as well as to additional information about how all stem cells work in general.”

Brinster's work could eventually prove useful in the treatment of certain types of infertility in men, although complete spermatogenesis was established in only 1.5 to 3 percent of seminiferous tubules in this experiment.

“Male infertility can be caused either by defective germ cells or by a testicular environment that fails to promote proper spermatogenesis,” Brinster said. “While several assisted reproductive technologies, such as in vitro fertilization or intracytoplasmic sperm injection, are now available for patients with low sperm

counts, infertile patients with Sertoli cell defects have limited options.”

The technique developed by Brinster and his colleagues may provide a new way of replacing defective Sertoli cells with healthy ones, which may initiate normal spermatogenesis in some infertile patients.

Brinster was joined in the research by Takashi Shinohara, now at Kyoto University, and **Kyle E. Orwig** and **Mary R. Avarbock** in Penn's School of Veterinary Medicine. The work was funded by the Japan Society for Promotion of Science, the National Institute of Child Health and Human Development, the Commonwealth and General Assembly of Pennsylvania and the Robert J. Kleberg Jr. and Helen C. Kleberg Foundation.

**PennHIP**®

PennHIP Administrative Center

3900 Delancey St. Philadelphia, PA 19104-6010

[www.vet.upenn.edu/pennhip/](http://www.vet.upenn.edu/pennhip/)

Dear PennHIP Members, Veterinarians, Pet Owners, and Dog Breeders:

I am pleased to announce that the University of Pennsylvania has once again become the home of PennHIP. Synbiotics and the University of Pennsylvania have reached an agreement that transferred the PennHIP license back to Penn on November 15, 2002. We at PennHIP would like to recognize Synbiotics (and before that, ICG) for the years of good management, helping to grow PennHIP to the size it is today. We are hopeful that this friendly departure will strengthen both entities. Like the OFA, PennHIP will now be a “not-for-profit” organization and we look forward to working with the American Kennel Club and other breed clubs.

We anticipate some confusion in the transition and we thank you in advance for your understanding and tolerance through this period. Penn's acquisition of PennHIP is an exceptional opportunity to put PennHIP on equal footing with other not-for-profit screening methods. The expanding body of published scientific articles provides comparative evidence that PennHIP is the superior screening method for hip dysplasia. We are excited about this new development and we look forward to widespread utilization of PennHIP to improve the hip quality of all dog breeds afflicted with hip dysplasia.

Visit our web site for periodic updates.

Thank you,

Gail K. Smith, V.M.D., Ph.D.

Director, PennHIP